← board
NRSN
NeuroSense Therapeutics Ltd.distress 5/10 · elevated risk$0.68+4%today-67% from 52w high
Neurology 1
Lead: Alzheimer Disease · est. market ~$8B (approx, global)
Revenue
pre-revenue
Liquidity
$0M
Runway
0.0 yrs
Shares 1y
0%
Price & events
-27.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
+4.4%
1D
-3.3%
1W
-11.6%
1M
-5.0%
3M
-29.2%
6M
-66.9%
1Y
-13.1%
2Y
—
5Y
-83.2%
All
Overview
- Market Cap
- $22.10M
- Volume
- 10.85K
- 52 Week Range
- $0.65 – $2.07
- Total Shares
- 32.56M
- Float Shares
- 23.34M
- Short %
- 2.09%
- % Held by Insiders
- 32.30%
- % Held by Institutions
- 1.07%
- RVOL
- 0.06x
- Beta
- 1.56
Pipeline stages · 1 programs
PrimeC
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-09-30 | Phase 2 | PrimeC | Alzheimer Disease | 8 | terminated |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 32,557,174 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $7 (+857% upside) · 3 analysts
- 2026-04-08D. Boral CapitalBuy
- 2026-03-25D. Boral CapitalBuy
- 2026-03-17D. Boral CapitalBuy
- 2026-03-10Roth CapitalBuy
- 2026-03-09D. Boral CapitalBuy
- 2025-12-22D. Boral CapitalBuy
Competitors — Alzheimer Disease
- LLYELI LILLY & Co$1094.4B · D3
- JNJJOHNSON & JOHNSON$617.4B · D0
- BMYBRISTOL MYERS SQUIBB CO$124.5B · D0
- AXSMAxsome Therapeutics, Inc.$12.3B · D0
- ARWRARROWHEAD PHARMACEUTICALS, INC.$12.3B · D3
- LNTHLantheus Holdings, Inc.$6.6B · D0
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- ABOSAcumen Pharmaceuticals, Inc.$157M · D6
- INMBInmune Bio, Inc.$47M · D5
- IGCIGC Pharma, Inc.$27M · D7
Recent news
- 2026-07-22NeuroSense Moves PrimeC Toward Health Canada Drug Submission for ALS - TipRanks
- 2026-07-22NeuroSense Therapeutics (NASDAQ: NRSN) eyes Canada NDS for ALS drug - Stock Titan
- 2026-07-22NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS - PR Newswire
- 2026-07-17NeuroSense Therapeutics (NRSN) Slides 2.3% as Sellers Test Key Support at $0.66 - Calendar Spread Trade - dars.gov.et
- 2026-07-09NeuroSense Therapeutics (NRSN) Edges Higher as Key Support Holds - Revenue Weighted - dars.gov.et
- 2026-07-04Price to earnings forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSN - TradingView
- 2026-06-29NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS - PR Newswire
- 2026-06-29NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS - PR Newswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.